← ANALYST RATINGS · TIPRANKS
Intellia Therapeutics (NTLA): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy3 Hold1 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $22.14, the highest $49.00, the lowest $9.00. The average is +93.9% from the last price of $11.42.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.50 → $12.00+4.3% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $15.00 | Hold | +31.3% | Reiterated | 15.10.26on TipRanks 07:30 | −1.1%next day +1.8% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 → $12.00−7.7% | Hold | +5.1% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.00 → $12.00−7.7% | Hold | +5.1% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.00 → $11.50−11.5% | Hold | +0.7% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 → $12.00−7.7% | Hold | +5.1% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.50 → $11.50−8.0% | Hold | +0.7% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $8.00 | Sell | −29.9% | Initiated | 06.10.26on TipRanks 09:25 | −3.5%next day −5.1% · 5 days −3.6% | ↗ |
| Unknown Analyst | Wells Fargo | $15.00 | Hold | +31.3% | Reiterated | 02.10.26on TipRanks Oct 6 09:25 | +0.4%next day +3.3% · 5 days +5.4% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $12.00 → $13.00+8.3% | Hold | +13.8% | Reiterated | 09.09.26on TipRanks 09:00 | −3.7%next day −1.7% · 5 days −4.8% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $25.00 | Buy | +118.9% | Reiterated | 09.09.26on TipRanks 07:08 | −3.7%next day −1.7% · 5 days −4.8% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 04.09.26on TipRanks Sep 7 12:10 | +0.9%next day +0.5% · 5 days −5.6% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $29.00 | Buy | +153.9% | Reiterated | 14.08.26on TipRanks 12:35 | +0.9%next day +2.0% · 5 days +9.2% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $15.00 | Hold | +31.3% | Assigned | 10.08.26on TipRanks 08:21 | +0.7%next day +0.3% · 5 days +0.6% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $16.00 → $24.00+50.0% | Buy | +110.2% | Upgrade | 07.08.26on TipRanks 07:55 | +5.6%next day +0.7% · 5 days −0.7% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $19.00 → $17.00−10.5% | Hold | +48.9% | Reiterated | 07.08.26on TipRanks 06:50 | +5.6%next day +0.7% · 5 days −0.7% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $49.00 | Buy | +329.1% | Reiterated | 06.08.26on TipRanks Aug 7 16:16 | +2.6%next day +5.6% · 5 days +4.0% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $9.00 | Sell | −21.2% | Reiterated | 06.08.26on TipRanks Aug 7 08:35 | +2.6%next day +5.6% · 5 days +4.0% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $15.00 | Hold | +31.3% | Reiterated | 06.08.26on TipRanks Aug 7 07:26 | +2.6%next day +5.6% · 5 days +4.0% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 18:46 | +5.6%next day +0.7% · 5 days −0.7% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $9.00 | Sell | −21.2% | Downgrade | 15.07.26on TipRanks 17:25 | −8.5%next day −3.1% · 5 days −4.7% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $8.00 | Sell | −29.9% | Reiterated | 13.05.26on TipRanks May 14 08:07 | +1.5%next day −9.1% · 5 days −14.0% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $13.00 → $17.00+30.8% | Hold | +48.9% | Assigned | 13.05.26on TipRanks 06:35 | +1.5%next day −9.1% · 5 days −14.0% | ↗ |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $15.00 | Hold | +31.3% | Reiterated | 12.05.26on TipRanks May 13 04:40 | −2.8%next day +1.5% · 5 days −14.1% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | $28.00 → $30.00+7.1% | Buy | +162.7% | Reiterated | 28.04.26on TipRanks 05:50 | +1.7%next day −5.7% · 5 days −0.9% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $30.00 | Buy | +162.7% | Reiterated | 27.04.26on TipRanks 14:05 | −4.5%next day +1.7% · 5 days +6.0% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $35.00 | Buy | +206.5% | Reiterated | 27.04.26on TipRanks 13:25 | −4.5%next day +1.7% · 5 days +6.0% | ↗ |
| Jack Allen★★★★★★★★★★#12322 · hits 30% · avg −16.3% | Robert W. Baird | $7.00 → $13.00+85.7% | Hold | +13.8% | Reiterated | 27.04.26on TipRanks 12:20 | −4.5%next day +1.7% · 5 days +6.0% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 02.03.26on TipRanks 08:15 | +12.0%next day −11.0% · 5 days −8.9% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $33.00 → $27.00−18.2% | Buy | +136.4% | Reiterated | 07.11.25on TipRanks 15:00 | −22.8%next day +0.6% · 5 days −8.8% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $24.00 → $14.00−41.7% | Buy | +22.6% | Reiterated | 07.11.25on TipRanks 05:15 | −22.8%next day +0.6% · 5 days −8.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Intellia Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $20.50 at a price of $12.06 (+70.0%); now: $19.91 at $11.42 (+74.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 9 | 5 | 5 | 4 | 4 |
| Buy | 5 | 5 | 4 | 3 | 2 | 2 |
| Hold | 6 | 4 | 4 | 3 | 3 | 3 |
| Sell | 4 | 4 | 4 | 3 | 2 | 1 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.80 (from $-0.89 to $-0.72). Last quarter: $-0.80.
Sales
Next quarter’s sales estimate — $10M (from $0M to $15M). Last quarter: $8M.
Best top-analyst consensus in the sector · Healthcare
About Intellia Therapeutics
- CEO: John Leonard
- Employees: 377
- 40 Erie Street, Cambridge, MA, 02139, US
- www.intelliatx.com
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗